The Sensor That Was Built for Diabetics and Found a Much Larger Market
Continuous glucose monitors are wearable electrochemical sensors whose subcutaneous filament electrode measures interstitial fluid glucose concentration every one to five minutes, transmitting the data wirelessly to a smartphone application that displays the user's glucose trend in real time and alerts them when glucose rises or falls outside the target range that the user or their clinician has configured. The clinical market for CGM, dominated by Type 1 diabetic patients whose insulin-dependent glucose management requires the continuous visibility that CGM provides over the fingerstick glucose measurements that capture only a single moment in the glucose profile, and the growing Type 2 diabetic market whose insulin-using patients benefit similarly from continuous glucose visibility, has generated the sensor manufacturing scale, wireless data platform maturity, and wearable miniaturisation that has brought CGM sensor cost and accuracy to the levels that non-diabetic consumer applications can commercially justify. The CGM market for diabetes management, valued at over $8 billion in 2025 and dominated by Dexcom and Abbott Freestyle Libre whose combined market share exceeds seventy-five percent, provided the manufacturing and commercial infrastructure whose scale economics enabled the consumer wellness CGM products that both companies and multiple startups have launched for the non-diabetic population whose glucose monitoring interest is driven not by insulin management but by the metabolic health, diet optimisation, athletic performance, and longevity motivation that the quantified self and wellness markets represent.
The consumer wellness CGM market, launched commercially in 2024 with Dexcom's Stelo and Abbott's Lingo products whose FDA clearance for over-the-counter sale without a prescription established the regulatory framework for non-diabetic CGM, is growing rapidly from its initial launch phase toward the $2.3 billion market projection that analysts forecast by 2029 as consumer awareness of metabolic health monitoring expands and the device cost and wearing duration improve toward the mass-market accessibility threshold. The consumer CGM market's growth depends on the commercial proposition that continuous glucose data changes non-diabetic user behaviour in ways that improve metabolic health outcomes, whose evidence base from randomised controlled trials in non-diabetic populations is accumulating but remains less mature than the extensive clinical evidence for CGM in diabetes management.
Dexcom Stelo and Abbott Lingo
Dexcom's Stelo, the first over-the-counter CGM product approved by the FDA for adults without diabetes or without insulin-using diabetes, launched commercially in 2024 as a fifteen-day wear sensor whose glucose data is displayed through the Stelo smartphone application without the customised alert thresholds and clinical decision support that Dexcom's G7 and G6 diabetes management products provide. The Stelo's glucose display in the context of meals, exercise, sleep, and stress, whose correlation with the user's reported activities creates the personalised glucose response pattern that the consumer metabolic health application positions as actionable insight for dietary and lifestyle optimisation, creates the user experience that Dexcom's consumer CGM marketing emphasises in the athletic performance, weight management, and general wellness segments. Abbott's Lingo, launched as a consumer CGM in the United Kingdom and expanding into other markets, uses Abbott's Freestyle Libre sensor platform in a consumer-oriented presentation whose coaching and behavioural insights application layer translates the glucose data into the dietary and lifestyle recommendations that consumer health applications provide rather than the clinical glucose management data that diabetes care applications display.
Levels Health, the US metabolic health company whose CGM-integrated platform combines the sensor hardware from Dexcom or Abbott with Levels' proprietary software application whose dietary response scoring, meal logging, and personalised metabolic insights create the consumer metabolic health coaching product, has built a subscription business model that monetises the CGM data through software services rather than through sensor hardware margin. Its waitlist model that created early demand and its partnership with major media platforms and health influencers whose metabolic health content drove awareness of CGM in the non-diabetic wellness market created the consumer education infrastructure that preceded Dexcom and Abbott's own consumer CGM product launches. The competitive dynamic between Levels' software-first model and the hardware company direct-to-consumer models of Dexcom Stelo and Abbott Lingo will determine whether the consumer CGM value chain concentrates in the hardware manufacturer or fragments between hardware suppliers and software platform companies.
The Clinical Evidence Question and the Wellness Market
The consumer CGM market's commercial sustainability depends on whether the glucose data that non-diabetic users collect through continuous monitoring translates into the behaviour change and health outcome improvement that justifies the recurring sensor cost of approximately $100 to $200 per month that continuous CGM wear requires. The randomised controlled trial evidence for CGM-guided dietary intervention in non-diabetic populations is accumulating through the studies that Stanford, King's College London, and other academic centres are conducting, but remains insufficient to support the clinical health claims that would qualify consumer CGM for health insurance reimbursement in the non-diabetic population, whose out-of-pocket payment is the current commercial model that limits the addressable market to the wellness consumer segment whose health technology spending is above average.
Top 10 Companies in Consumer and Wellness Continuous Glucose Monitoring Globally
- Dexcom (Stelo): US CGM company with the first FDA-cleared over-the-counter CGM for non-diabetic adults; its Stelo fifteen-day sensor and its consumer metabolic health application create the CGM market leader's direct entry into the wellness market whose consumer product launch leverages Dexcom's G7 sensor platform engineering.
- Abbott (Lingo): US medical device company with Lingo consumer CGM based on Freestyle Libre sensor platform; its UK launch and international expansion and its coaching application layer create the competing consumer CGM product whose Libre sensor manufacturing scale creates the cost structure for mass-market wellness CGM deployment.
- Levels Health: US metabolic health software company with CGM-integrated platform for dietary response analysis; its software subscription model and its partnership with Dexcom and Abbott sensors create the consumer CGM software layer that monetises glucose data through metabolic insights and dietary coaching rather than sensor hardware margin.
- Nutrisense: US metabolic health company with CGM-integrated dietitian coaching and glucose response analysis; its human dietitian coaching layer combined with CGM data and its subscription model create the premium consumer CGM service that positions professional nutrition guidance as the value-added differentiator above the self-service CGM applications.
- Signos: US weight loss CGM company with glucose-based weight management programme; its AI weight loss recommendations based on CGM glucose response data and its weight loss clinical outcomes focus create the consumer CGM product positioned for the weight management market whose intersection with the GLP-1 drug market creates the commercial context for glucose monitoring in the metabolic health intervention market.
- Supersapiens: US-European athletic performance CGM company with Abbott Libre Sense glucose sport biosensor integration; its athletic performance glucose monitoring for endurance sports and its professional sports team partnerships create the sports performance CGM application whose elite athlete adoption creates the aspirational consumer CGM positioning for the fitness-motivated wellness consumer.
- Medtronic (Simplera): US medical device company with Simplera disposable CGM and consumer CGM development; its diabetes CGM heritage and its integrated artificial pancreas system create the medical device company's CGM commercial position in both the clinical and the consumer market whose product differentiation between diabetes management and wellness applications is the commercial strategy question its consumer product development must resolve.
- January AI: US metabolic health AI company with glucose prediction and dietary response modelling from CGM data; its machine learning glucose prediction that estimates glucose response to foods without continuous CGM and its CGM data integration create the AI metabolic health platform whose predictive capability extends the CGM data value beyond the measurement window of each individual sensor wear period.
- ZOE: UK personalised nutrition company with CGM-integrated dietary response profiling; its PREDICT study data from King's College London and its CGM-informed personalised nutrition recommendations create the consumer CGM company whose academic research foundation and its UK medical credibility differentiate its metabolic health platform from the US wellness-market-focused competitors.
- Samsung (Galaxy Ring): South Korean electronics company with Galaxy Ring and wearable health monitoring development towards non-invasive glucose monitoring; its wearable health sensor integration and its research investment in non-invasive optical glucose monitoring create the consumer electronics company whose non-invasive glucose sensing ambition represents the technology frontier that would eliminate the subcutaneous sensor requirement that current CGM technology demands.